Table 3

Multivariate analysis for relapse-free and overall survival of the 45 non-LMPa ovarian cancer cases with optimal surgical cytoreductive therapy

VariableRelative risk of relapse (95% CI)P
Relapse-free survival
 Age
  >60 yr vs. ≤60 yr1.4 (0.4–4.8)0.55
 FIGO stage
  III/IV vs. I/II1.2 (0.3–4.7)0.81
 Tumor grade
  III vs. I/II2.0 (0.5–7.7)0.31
 Chr1 Sat2 hypomethylation
  >2 vs. ≤24.1 (1.2–14.7)0.029
Overall survival
 Age
  >60 yr vs. ≤60 yr7.2 (1.5–34.3)0.014
 FIGO stage
  III/IV vs. I/II0.2 (0.1–1.0)0.049
 Tumor grade
  III vs. I/II0.3 (0.1–1.8)0.19
 Chr1 Sat2 hypomethylation
  >2 vs. ≤29.4 (2.1–41.5)0.003
  • a LMP, low malignant potential; FIGO, Fédération Internationale des Gynaecologistes et Obstetristes; CI, confidence interval.